Orna Therapeutics
Orna Therapeutics, founded in 2019, is innovating RNA therapeutics by developing engineered circular RNA (oRNA) with applications in various disease areas, including cancer and infectious diseases.
Reshaping RNA Therapeutics
Orna Therapeutics is at the forefront of reshaping RNA therapeutics by transitioning from linear to circular RNA. This novel approach aims to enhance treatment possibilities across a range of diseases. Their engineered circular RNA, known as oRNA, holds significant advantages over traditional linear RNA, including improved stability and efficiency.
Lead Program and Applications
Orna Therapeutics is developing a broad spectrum of applications for oRNA in areas such as cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity. A leading program features an in situ CAR therapy, utilizing oRNA and proprietary lipid nanoparticles for direct delivery to immune cells. This innovative approach aims to improve therapeutic outcomes.
Founding and Development
Founded in 2019, Orna Therapeutics emerged from research conducted at the Massachusetts Institute of Technology (MIT). The company was built by MPM Capital and its affiliate, BioImpact Capital. Grounded in cutting-edge science, the company focuses on pioneering RNA-based treatments.
Collaborations and Partnerships
Orna Therapeutics collaborates with various partners to advance its technology and reach. For instance, they are working with Simnova Biotherapeutics to develop market opportunities in China and with Merck for vaccine development. These collaborations aim to leverage the strengths of each partner to drive innovation in RNA therapeutics.
Headquarters and Location
Orna Therapeutics is headquartered at 500 Forge Road, Watertown, MA 02472. This location serves as the central hub for their research, development, and administrative operations, enabling the company to push the boundaries of RNA therapeutics.